Related Experiment Videos
Phase I trial of elactocin
E S Newlands1, G J Rustin, M H Brampton
1Department of Medical Oncology, Charing Cross Hospital, London, UK.
British Journal of Cancer
|August 1, 1996
Summary
Elactocin, an anti-tumour antibiotic, showed potent in vitro activity but caused severe anorexia and malaise in phase I trials. No tumour responses were observed, leading to a recommendation against further elactocin studies.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Elactocin is a novel antibiotic with demonstrated in vitro anti-tumour activity.
- Preclinical studies suggested potential efficacy against various cancer types.
Purpose of the Study:
- To evaluate the safety and tolerability of elactocin in cancer patients.
- To identify the dose-limiting toxicity and maximum tolerated dose of elactocin.
- To explore preliminary anti-tumour activity of elactocin across different administration schedules.
Main Methods:
- A phase I clinical trial was conducted.
- Multiple administration schedules were investigated, including 1-hour infusions (3-weekly, weekly, daily x 5), 24-hour infusions (3-weekly), and continuous 5-day intravenous infusion.
- Dose-limiting toxicities and objective tumour responses were assessed.
Main Results:
- The dose-limiting toxicity for elactocin was identified as profound anorexia and malaise across all tested schedules.
- No partial or complete anti-tumour responses were observed in patients treated with elactocin.
- The observed toxicities were severe and consistent regardless of the administration schedule.
Conclusions:
- Elactocin exhibits significant toxicity, primarily severe anorexia and malaise, at doses tested in this phase I trial.
- The lack of observed anti-tumour efficacy, coupled with dose-limiting toxicities, suggests elactocin is not a viable candidate for further clinical development.
- Further clinical trials of elactocin are not recommended based on these findings.